Bariatric surgery reduced lifetime cardiovascular disease risk by 8.6% compared to just 1.7% with GLP-1 receptor agonist medications like semaglutide and tirzepatide in 812 adults with obesity tracked for one year. Surgery also achieved superior weight loss (27.8% vs 11.1%) and more favorable lipid changes including greater LDL reductions and HDL increases. This head-to-head comparison represents crucial real-world evidence as millions face the choice between surgical and pharmaceutical weight management approaches. The findings illuminate a critical distinction: while both interventions showed similar short-term cardiovascular benefits, surgery's dramatic advantage in lifetime risk reduction suggests fundamentally different long-term health trajectories. For adults considering weight management strategies, this data challenges the prevailing narrative that newer GLP-1 medications might eventually match surgical outcomes. The 5-fold difference in lifetime cardiovascular protection, combined with surgery's superior metabolic improvements, positions bariatric procedures as potentially transformative rather than merely cosmetic interventions. However, the study's one-year timeframe limits assessment of medication durability, and surgical risks weren't quantified. This research reinforces surgery's role as the gold standard for severe obesity treatment while highlighting GLP-1 drugs' value as important but less comprehensive interventions.